Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Stephen Looney Recognized as Lawyer of the Year in Tax Law in Orlando
ORLANDO, Florida, March 31 -- Dean Mead, a law firm, issued the following news release:
* * *
Stephen Looney Recognized as Lawyer of the Year in Tax Law in Orlando
In their April 2026 publication, Orlando Magazine has recognized Stephen R. Looney as "Lawyer of the Year" for Tax Law in Orlando. A unique distinction, as only a single lawyer in each practice area within a designated metropolitan area is recognized.
Per the publication, "Receiving this designation reflects the high level of respect a lawyer has earned among other leading lawyers in the same communities and same practice areas for
... Show Full Article
ORLANDO, Florida, March 31 -- Dean Mead, a law firm, issued the following news release:
* * *
Stephen Looney Recognized as Lawyer of the Year in Tax Law in Orlando
In their April 2026 publication, Orlando Magazine has recognized Stephen R. Looney as "Lawyer of the Year" for Tax Law in Orlando. A unique distinction, as only a single lawyer in each practice area within a designated metropolitan area is recognized.
Per the publication, "Receiving this designation reflects the high level of respect a lawyer has earned among other leading lawyers in the same communities and same practice areas fortheir abilities, their professionalism, and their integrity."
* * *
Featured Professionals
Stephen R. Looney
Attorney
[email protected]
O: (407) 428-5128 F: (407) 423-1831
* * *
Original text here: https://www.deanmead.com/stephen-looney-recognized-as-lawyer-of-the-year-in-tax-law-in-orlando/
[Category: BizLaw/Legal]
Mark Barnes Co-Authored Article In Journal of Law, Medicine & Ethics
BOSTON, Massachusetts, March 31 [Category: BizLaw/Legal] -- Ropes and Gray, a law firm, issued the following news:
* * *
Mark Barnes Co-Authored Article In Journal of Law, Medicine & Ethics
Health care partner Mark Barnes co-authored an article in the Journal of Law, Medicine & Ethics outlining international ethical principles for the collection, use, and sharing of human biospecimens and associated data.
The article titled International Ethical Principles for Banking and Secondary Research Use of Human Biospecimens and Associated Data: The Seattle Principles explains that the secondary research
... Show Full Article
BOSTON, Massachusetts, March 31 [Category: BizLaw/Legal] -- Ropes and Gray, a law firm, issued the following news:
* * *
Mark Barnes Co-Authored Article In Journal of Law, Medicine & Ethics
Health care partner Mark Barnes co-authored an article in the Journal of Law, Medicine & Ethics outlining international ethical principles for the collection, use, and sharing of human biospecimens and associated data.
The article titled International Ethical Principles for Banking and Secondary Research Use of Human Biospecimens and Associated Data: The Seattle Principles explains that the secondary researchuse of human biospecimens and associated clinical data is essential to scientific advances by industry and academia, but is governed by a patchwork of differing national regulations and characterized by uncertainty in applicable ethical principles.
The authors provide a set of ethical principles to address some of the challenges by ensuring better alignment in ethical practices related to biobanking the global use of human biospecimens. The authors note that these principles could serve as a basis for promoting more consistency among national regulations and policies. The ultimate goal is to develop an international framework for global biospecimen and data sharing.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/03/mark-barnes-co-authored-article-in-journal-of-law-medicine-ethics
Marcus & Millichap Arranges $3.1M Sale of Fully Occupied Retail Property in Wisconsin Rapids
ENCINO, California, March 31 -- Marcus and Millichap issued the following news release on March 30, 2026:
* * *
Marcus & Millichap Arranges $3.1M Sale of Fully Occupied Retail Property in Wisconsin Rapids
WISCONSIN RAPIDS, Wis. - Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of Rapids Plaza, a seven-tenant fully occupied retail center located in Wisconsin Rapids, Wisconsin, for $3.1 million.
"This center drew substantial investor interest thanks to its high
... Show Full Article
ENCINO, California, March 31 -- Marcus and Millichap issued the following news release on March 30, 2026:
* * *
Marcus & Millichap Arranges $3.1M Sale of Fully Occupied Retail Property in Wisconsin Rapids
WISCONSIN RAPIDS, Wis. - Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the sale of Rapids Plaza, a seven-tenant fully occupied retail center located in Wisconsin Rapids, Wisconsin, for $3.1 million.
"This center drew substantial investor interest thanks to its highhistorical occupancy, new roof, and positioning in front of a well-ranked Walmart," said Jeff Rowlett, senior managing director investments.
Rowlett and John Sfire, investment specialists in Marcus & Millichap's Milwaukee and Minneapolis offices, had the exclusive listing to market the property on behalf of the seller, Rapids Plaza, LLC. Rowlett procured the buyer, Above Grade Properties, LLC.
Rapids Plaza is located at 4551 8th St. S in Wisconsin Rapids' primary retail corridor. The fully occupied retail center sits on a high-traffic corner and is shadow-anchored by Walmart. Built in 2003, the 16,620-square-foot property includes tenants such as Papa Murphy's, AT&T, Jackson Hewitt and Shopko Optical.
* * *
About Marcus & Millichap, Inc. (NYSE: MMI)
Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. As of December 31, 2025, the company had 1,808 investment sales and financing professionals in over 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate. The company also offers market research, consulting and advisory services to clients. Marcus & Millichap closed 8,818 transactions in 2025, with a sales volume of approximately $50.9 billion. For additional information, please visit www.MarcusMillichap.com.
* * *
Original text here: https://www.marcusmillichap.com/news-events/press/2026/03/03-30-rapidsplaza
[Category: BizRealEstate]
Hausfeld Files U.S. Supreme Court Amicus Brief Defending Human Rights Accountability and American Jobs
WASHINGTON, March 31 -- Hausfeld, a law firm, issued the following news:
* * *
Hausfeld files U.S. Supreme Court amicus brief defending human rights accountability and American jobs
Hausfeld has filed an amicus curiae brief (https://www.hausfeld.com/media/ibdlx504/24-856-amicus-brief.pdf) in the U.S. Supreme Court on behalf of leading professors of Economics and Political Science and Oxfam America in support of the plaintiffs in the case against Cisco Systems, Inc. Plaintiffs allege that Cisco aided and abetted human rights abuses against religious minorities in China. The brief addresses aiding
... Show Full Article
WASHINGTON, March 31 -- Hausfeld, a law firm, issued the following news:
* * *
Hausfeld files U.S. Supreme Court amicus brief defending human rights accountability and American jobs
Hausfeld has filed an amicus curiae brief (https://www.hausfeld.com/media/ibdlx504/24-856-amicus-brief.pdf) in the U.S. Supreme Court on behalf of leading professors of Economics and Political Science and Oxfam America in support of the plaintiffs in the case against Cisco Systems, Inc. Plaintiffs allege that Cisco aided and abetted human rights abuses against religious minorities in China. The brief addresses aidingand abetting (accessorial) liability under the Alien Tort Statute (ATS), 28 U.S.C. Sec. 1350, and the Torture Victim Protection Act (TVPA), 28 U.S.C. Sec. 1350 note.
Drawing on decades of research and policy experience, the amici rebut claims by Cisco and their supporters, such as the U.S. Chamber of Commerce, that accessorial liability will damage the reputation and bottom line of U.S. corporations, deter investment in less developed countries, harm economic development and human rights, or undermine U.S. competitiveness. The brief explains that there is no empirical basis for these assertions and that liability for aiding and abetting grave abuses is an economically efficient way to deter corporate complicity, promote responsible investment, and support long term development and stability.
The amici further argue that accountability under the ATS and TVPA promotes fair competition by leveling the playing field between companies that comply with international human rights norms and those that seek to profit from abuses. A central focus of the brief is U.S. technology companies' provision of advanced surveillance and AI tools to authoritarian regimes: the amici contend that aiding and abetting liability for such conduct will help protect American workers and jobs by disincentivizing U.S. firms from enabling worker suppression and artificial wage depression abroad that fuel offshoring at the expense of U.S. workers.
The brief is signed by distinguished experts including Nobel laureates in economics Joseph Stiglitz and Simon Johnson, as well as Geoffrey Heal, Gabriel Zucman, Marc Goergen, Mircea Raianu and political scientist Adam Dean. Oxfam America, a global anti poverty organization with extensive expertise on corporate human rights impacts, also joins as amicus. The Court's decision will have significant implications for the future of the ATS and TVPA, corporate responsibility for aiding and abetting violations of international law, and the protection of vulnerable communities abroad and in the United States.
* * *
Related People
Michael D. Hausfeld
Jeannine M. Kenney
Mary Sameera Van Houten Harper
Amanda Lee-Dasgupta
Percy Metcalfe
* * *
Original text here: https://www.hausfeld.com/en-us/news/hausfeld-files-us-supreme-court-amicus-brief-defending-human-rights-accountability-and-american-jobs
[Category: BizLaw/Legal]
Gary Kalbaugh Moderates Panel on the GENIUS Act
NEW YORK, March 31 -- Cahill Gordon and Reindel, a law firm, issued the following news:
* * *
Gary Kalbaugh Moderates Panel on the GENIUS Act
Gary Kalbaugh will moderate the "The GENIUS Act in Practice: Key Questions for Stablecoin Regulation" with Gov. Michael Barr (Federal Reserve Board), Hon. Summer Mersinger (CEO of the Blockchain Association), Greg Xethalis (General Counsel of Multicoin Capital), and Alex Pollock (Senior Fellow, Mises Institute and former President and CEO of the Federal Home Loan Bank of Chicago).
Together, the panelists will explore the future of stablecoins and their
... Show Full Article
NEW YORK, March 31 -- Cahill Gordon and Reindel, a law firm, issued the following news:
* * *
Gary Kalbaugh Moderates Panel on the GENIUS Act
Gary Kalbaugh will moderate the "The GENIUS Act in Practice: Key Questions for Stablecoin Regulation" with Gov. Michael Barr (Federal Reserve Board), Hon. Summer Mersinger (CEO of the Blockchain Association), Greg Xethalis (General Counsel of Multicoin Capital), and Alex Pollock (Senior Fellow, Mises Institute and former President and CEO of the Federal Home Loan Bank of Chicago).
Together, the panelists will explore the future of stablecoins and theirnewly regulated framework under the GENIUS Act.
To learn more about this webinar, click here (https://fedsoc.org/events/the-genius-act-in-practice-key-questions-for-stablecoin-regulation).
* * *
Attorney
Gary E. Kalbaugh
Partner
212.701.3505
GKalbaugh@cahill.com
* * *
Original text here: https://www.cahill.com/news/events/2026-03-31-gary-kalbaugh-moderates-panel-on-the-genius-act
[Category: BizLaw/Legal]
GSK: Bepirovirsen Accepted for Regulatory Review in China as a Potential First-In-Class Functional Cure for Chronic Hepatitis B
LONDON, England, March 31 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 30, 2026:
* * *
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
* Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials
* An estimated 75 million people in China live with chronic hepatitis B1, a leading cause of liver cancer/2
* Bepirovirsen granted Breakthrough Therapy designation
*
GSK plc (LSE/NYSE: GSK)
... Show Full Article
LONDON, England, March 31 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 30, 2026:
* * *
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
* Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials
* An estimated 75 million people in China live with chronic hepatitis B1, a leading cause of liver cancer/2
* Bepirovirsen granted Breakthrough Therapy designation
*
GSK plc (LSE/NYSE: GSK)today announced that the China National Medical Products Administration (NMPA) has accepted for review a new drug application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO), for the treatment of adults with chronic hepatitis B (CHB).
Chronic hepatitis B is a major public health challenge, affecting more than 250 million people worldwide and an estimated 75 million people in China/1. The current standard of care - typically nucleos(t)ide analogues - often requires lifelong therapy and the functional cure rates remain low, typically only 1%./3 Functional cure occurs when the hepatitis B virus DNA and viral protein - hepatitis B surface antigen (HBsAg) - are undetectable in the blood for at least 24 weeks after stopping all treatment, indicative of the disease being controlled by the immune system without medication. Functional cure is associated with significant reduction in the risk of long-term liver complications, including liver cancer./4 Each year, in China, approximately 450,000 deaths are caused by CHB1.
The regulatory submission is supported by positive results from the B-Well 1 and B-Well 2 Phase III trials, where bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate. Functional cure rates were significantly higher with bepirovirsen plus standard of care compared with standard of care alone across all ranked endpoints, including in patients with lower baseline HBsAg levels where an even greater effect was observed. Bepirovirsen demonstrated an acceptable safety and tolerability profile consistent with previous studies. These data will be presented at a congress and submitted for scientific peer-reviewed publication in 2026.
Bepirovirsen was granted Breakthrough Therapy designation in China in August 2021, which is intended to expedite the review of investigational drugs with potential for substantial improvement over available therapies.
Clinical trial programme
B-Well 1 [NCT05630807] and B-Well 2 [NCT 05630820] trials are global multi-centre, randomised, double-blind, placebo-controlled trials conducted in 29 countries. They assessed the efficacy, safety, pharmacokinetic profile, and the durability of functional cure in nucleos(t)ide analogue (NA)-treated in non-cirrhotic participants with CHB and baseline surface antigen (HBsAg) 3000 IU/ml. The primary endpoint assessed the proportion of participants achieving functional cure in patients with baseline surface antigen (HBsAg) 3000 IU/ml. A key ranked secondary endpoint evaluated functional cure in patients with baseline HBsAg 1000 IU/ml.
* * *
About chronic hepatitis B
Hepatitis B is a viral infection that can cause both acute and chronic liver disease. Chronic hepatitis B occurs when the immune system is unable to clear the virus, resulting in long-lasting infection. CHB affects more than 250 million people worldwide. Each year, the disease causes approximately 1.1 million deaths, and approximately 450,000 deaths in China.1 Many patients often require lifelong antiviral therapy for viral suppression; making functional cure a critical goal in disease management.
* * *
About bepirovirsen
Bepirovirsen is a triple action investigational antisense oligonucleotide (ASO), designed to recognise and orchestrate the destruction of the genetic components (i.e. mRNA and pregenomic RNA) of the hepatitis B virus that can lead to chronic disease, potentially allowing a person's immune system to regain control. Bepirovirsen inhibits the replication of the viral genome in the body, suppresses the level of hepatitis B surface antigen (HBsAg) in the blood, and stimulates the immune system to increase the chances of a durable and sustained response.
Bepirovirsen is also being evaluated as a potential backbone therapy for future sequential treatment strategies aimed at expanding functional cure to broader patient populations.
GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated with them on its development. Bepirovirsen has been recognised by global regulatory authorities for its innovation and potential to address significant unmet need in hepatitis B, with Fast Track designation from the US FDA, Breakthrough Therapy designation in China and SENKU designation in Japan. Bepirovirsen is currently not approved anywhere in the world.
* * *
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
* * *
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.
* * *
References
1./ WHO Global Hepatitis Report 2024. Available at https://www.who.int/publications/i/item/9789240091672 (last accessed March 2026)
2./ Rumgay H et al . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598-1606. doi: 10.1016/j.jhep.2022.08.021
3./ Slaets, L. et al. "Systematic review with meta-analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy" in GastroHep 2, 106-116 (2020)
4./ EASL, "Clinical Practice Guidelines on the management of hepatitis B virus infection" in Journal of Hepatology Volume 83, Issue 2, August 2025, Pages 502-583. Available at: https://www.sciencedirect.com/science/article/pii/S0168827825001746 (last accessed: January 2026)
* * *
Original text here: https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-china-as-a-potential-first-in-class-functional-cure-for-chronic-hepatitis-b/
[Category: BizPharmaceuticals]
Ameresco Partners With Saginaw Public Schools to Upgrade District Wide LED Lighting
FRAMINGHAM, Massachusetts, March 31 [Category: BizEnergy] -- Ameresco, a cleantech integrator specializing in energy efficiency and renewable energy, posted the following news release on March 30, 2026:
* * *
Ameresco Partners with Saginaw Public Schools to Upgrade District Wide LED Lighting
Comprehensive lighting modernization to drive efficiency, reduce costs, and support student success through sustainable infrastructure
*
Ameresco, Inc., (NYSE: AMRC), a leading energy infrastructure solutions provider, today announced a district wide LED lighting upgrade project at Saginaw Public School
... Show Full Article
FRAMINGHAM, Massachusetts, March 31 [Category: BizEnergy] -- Ameresco, a cleantech integrator specializing in energy efficiency and renewable energy, posted the following news release on March 30, 2026:
* * *
Ameresco Partners with Saginaw Public Schools to Upgrade District Wide LED Lighting
Comprehensive lighting modernization to drive efficiency, reduce costs, and support student success through sustainable infrastructure
*
Ameresco, Inc., (NYSE: AMRC), a leading energy infrastructure solutions provider, today announced a district wide LED lighting upgrade project at Saginaw Public SchoolDistrict, advancing its commitment to reducing energy consumption and lowering operating costs across all facilities. The comprehensive initiative will modernize lighting systems throughout the district, improve overall building efficiency, and create brighter, more consistent learning and working environments for students and staff. By investing in energy-efficient LED technology, the district is taking a proactive approach to sustainability while redirecting long-term savings back into educational programs and student support services.
Saginaw Public Schools MI Athletic Field
The project includes a comprehensive LED lighting retrofit with lighting controls across 12 schools, three service related facilities, and the district's Board of Education administration building. In total, the project will replace more than 12,000 lighting fixtures with high efficiency LED technology and modern control systems.
The project is structured as an energy savings performance contract (ESPC), with guaranteed energy savings, and is expected to reduce electricity use while generating annual cost savings for the district. Installation work began in early April and is expected to be completed by August 2026.
"This lighting project is a smart investment in both our operations and our long-term sustainability goals," said Tim Furtaw II, Executive Director of Facilities for Saginaw Public Schools. "By significantly reducing energy consumption and delivering guaranteed savings, we're lowering operating costs, improving lighting quality across our schools, and reinvesting those savings back into our district to support students and staff for years to come. Furthermore, after an exhaustive search for a non-proprietary, non-manufacturer-led energy-saving performance contract company, Ameresco fit the bill perfectly for what I envisioned. Ameresco worked closely with me and my facilities staff to ensure we were getting a project that fit our needs and saved me a lot of time handling the research, engineering and bidding documents to ultimately getting this project off the ground!"
"Projects like this are about delivering practical, long term value," said Lou Maltezos, President of Central & Western USA, Canada Regions at Ameresco. "Upgrading lighting across the district improves efficiency, enhances visibility, and helps drive cost savings while supporting reliable school facilities."
Upon completion, the district-wide LED upgrade will position the district for long-term operational efficiency and environmental responsibility. By modernizing its lighting infrastructure, the district is not only reducing energy consumption and maintenance costs, but also creating brighter, more comfortable spaces that support teaching and learning. This collaboration reflects a shared commitment to fiscal stewardship, sustainability, and investing in infrastructure that delivers meaningful benefits for students, staff, and the broader community.
To learn more about ESPC and Energy Performance Contracting offered by Ameresco, visit www.ameresco.com/espc-energy-savings-performance-contract/.
* * *
About Ameresco, Inc.
Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the global energy transition. Our comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. As a trusted full-service partner, Ameresco shows the way by reducing energy use and delivering energy infrastructure solutions to Federal, state and local governments, utilities, data centers, educational and healthcare institutions, housing authorities, and commercial and industrial customers. Headquartered in Framingham, MA, Ameresco has more than 1,500 employees providing local expertise in North America and Europe. For more information, visit www.ameresco.com.
The announcement of a customer's entry into a project contract is not necessarily indicative of the timing or amount of revenue from such contract, of Ameresco's overall revenue for any particular period or of trends in Ameresco's overall total project backlog. This project was included in Ameresco's previously reported contracted backlog as of December 31, 2025.
* * *
Original text here: https://www.ameresco.com/ameresco-partners-with-saginaw-public-schools-to-upgrade-district-wide-led-lighting/pr
